Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jul;174(2):323-5.
doi: 10.1111/bjh.13765. Epub 2015 Sep 25.

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma

Allison Rosenthal  1 , Shaji Kumar  2 , Craig Hofmeister  3 , Jacob Laubach  4 , Ravi Vij  5 , Amylou Dueck  1 , Katherine Gano  1 , A Keith Stewart  6
Affiliations
Clinical Trial

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma

Allison Rosenthal et al. Br J Haematol. 2016 Jul.
No abstract available

Keywords: alisertib; aurora kinase; bortezomib; multiple myeloma; relapse.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression Free Survival (N=26, Events=22, Median=5.9 months, 95% CI 4.1 – 15.8 months)
See this image and copyright information in PMC

References

    1. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006;12:6869–6875. - PubMed
    1. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo J-A, Fingert H, Baselga J, Tabernero J. Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2012;18:4764–4774. - PubMed
    1. Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA, Infante JR. Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research. 2012;18:4775–4784. - PubMed
    1. Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467–1473. - PubMed
    1. Falchook G, Kurzrock R, Gouw L, Hong D, McGregor K, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Investigational New Drugs. 2014;32:1181–1187. - PMC - PubMed